6990 — Sichuan Kelun-Biotech Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$108.71bn
- HK$103.19bn
- CNY2.06bn
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN
Brief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To BOC Structured Deposit III For RMB400 MLN
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT In First-Line TNBC
Brief: Sichuan Kelun-Biotech Biopharmaceutical Receives NMPA IND approval For Skb565
Brief: Kelun-Biotech Receives A Clinical Trial Notice For Its First Dual-Payload Adc Skb565
Brief: Sichuan Kelun-Biotech Biopharma Says Primary Endpoint Met For Phase 3 Study Of Lung Cancer Treatment
Brief: Sichuan Kelun-Biotech Biopharmaceutical To Place 5.84 Mln H Shares At HK$470.2 Per Share
Brief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes For CZB Structured Deposit V Of RMB200 Million
Brief: Sichuan Kelun-Biotech Biopharmaceutical Receives RMB602.5 Million From Medilink Therapeutics For Out-Licensing Of Yl201
Brief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes For CZB Structured Deposit III Of Rmb190 Million On April 22
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal
Merck rises after co and partner Kelun's lung cancer combo meets late-stage trial goal
Sichuan Kelun-Biotech at 4-week high on positive lung cancer trial with Merck
Brief: Sichuan Kelun-Biotech Biopharmaceutical says NDA Accepted For Review By NMPA
Kelun, Merck's lung cancer combo improves survival in late-stage China trial (updated)
Brief: Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial